Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
EXEL - Exelixis, Inc.
Market Cap 6.62B P/E 43.28 EPS this Y 92.30% Ern Qtrly Grth -
Income 207.76M Forward P/E 22.11 EPS next Y 17.60% 50D Avg Chg 5.00%
Sales 1.83B PEG 0.95 EPS past 5Y -4.31% 200D Avg Chg 13.00%
Dividend N/A Price/Book 2.58 EPS next 5Y 19.00% 52W High Chg -8.00%
Recommedations 1.90 Quick Ratio 3.16 Shares Outstanding 303.19M 52W Low Chg 37.00%
Insider Own 2.41% ROA 3.55% Shares Float 255.76M Beta 0.57
Inst Own 90.59% ROE 8.74% Shares Shorted/Prior 6.83M/8.85M Price 20.34
Gross Margin 96.04% Profit Margin 11.35% Avg. Volume 2,466,459 Target Price 26.74
Oper. Margin 17.05% Earnings Date Apr 30 Volume 4,906,656 Change 3.62%
Healthcare | Biotechnology | United States
About Exelixis, Inc.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis, Inc. News
04/17/24 Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth
04/16/24 Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
04/09/24 EXEL or REGN: Which Is the Better Value Stock Right Now?
03/28/24 Insiders Are Dumping These 10 Healthcare Stocks
03/23/24 4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
03/21/24 Exelixis, Inc.'s (NASDAQ:EXEL) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
03/17/24 30 Biggest Biotechnology Companies in the World
03/13/24 Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
03/11/24 The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
03/08/24 10 Biotech Stocks with Huge Potential
03/08/24 2 Biotech Stocks to Buy Hand Over Fist in March
03/07/24 Why Is Exelixis (EXEL) Up 10.9% Since Last Earnings Report?
03/07/24 10 Mid-Cap Stocks with Insider Purchases
03/06/24 3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
03/06/24 EXEL vs. REGN: Which Stock Is the Better Value Option?
03/02/24 4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
03/01/24 ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
02/29/24 Is Now The Time To Put Exelixis (NASDAQ:EXEL) On Your Watchlist?
02/27/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
02/27/24 Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments
EXEL Chatroom

User Image Acwild70 Posted - 20 hours ago

$EXEL why are we down so much premarket ?

User Image LHBhandy Posted - 1 day ago

$EXEL I sold 6 years ago for exactly the trading price today! Management keeps getting cheap options and dumping them into the market… Nothing has changed here…

User Image Acwild70 Posted - 1 day ago

$EXEL for no reason at all I guess

User Image Stock_Titan Posted - 3 days ago

$EXEL Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 https://www.stocktitan.net/news/EXEL/exelixis-to-release-first-quarter-2024-financial-results-on-tuesday-nt3ibgexfy6m.html

User Image ElijahJobs Posted - 6 days ago

$EXEL Very bullish.

User Image relative Posted - 1 week ago

$EXEL Brewing for a massive move. Watching how it reacts on key MA’s on Daily and Weekly. This can be a monster..

User Image erevnon Posted - 1 week ago

Barclays downgrades Exelixis $EXEL from Overweight to Equal-Weight and maintains the price target at https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Tangle22 Posted - 1 week ago

@ElijahJobs $Exel if upside then $5:00 up ?

User Image ElijahJobs Posted - 1 week ago

$EXEL The patent verdict must be near. Long and strong. JMO

User Image OtherOtttawaGuy Posted - 1 week ago

$EXEL Jumped on another small lot of shares at 22.80, will see by end of Apr if it pays off ...lol

User Image Doozio Posted - 1 week ago

$INSM chop chop huckleberries 2/22/20FOUR Thursday 🐑 low n da 🧠 can $exel in 🧠⏰

User Image UncleStock Posted - 1 week ago

$CORT $UTHR $EXEL $VRTX suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

User Image DefenseMania Posted - 1 week ago

$EXEL https://finance.yahoo.com/news/gilead-arcus-announce-amended-collaboration-220000800.html $GILD

User Image Acwild70 Posted - 2 weeks ago

$EXEL why the drop today?

User Image UncleStock Posted - 2 weeks ago

$CORT $UTHR $EXEL $VRTX suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

User Image OtherOtttawaGuy Posted - 2 weeks ago

$EXEL OtherOtttawaGuy less than a minute $EXEL Playing around with the Sentiment with two Bullish posts and its not moving the needle. Anyone know how it works

User Image OtherOtttawaGuy Posted - 2 weeks ago

$EXEL Gotten quiet around here, see on Investorsvillage note that Short Interest has dropped 6.8%, just need to get through that 24.13 top of last Dec...

User Image Tangle22 Posted - 2 weeks ago

$EXEL why pre market big drop

User Image ElijahJobs Posted - 03/31/24

$EXEL Someone bought 858,000 shares AH on Thursday.

User Image TheAnalyst88 Posted - 03/26/24

$EXEL bullish here for 2024 and we have several major catalysts for the remainder of 2024 and the next major one is listed here: Phase 3 completion date per the clinical trials . gov is 4/7/24 for A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma. the DFS and OS have already been met as of two months ago and was better than current standard of care. expect stock to rise significantly after these completion then either be bought out or run up until earnings where you can probably buy more on dip. https://www.clinicaltrials.gov/study/NCT03141177?spons=Bristol-Myers%20Squibb&aggFilters=phase:3&page=6&rank=60

User Image insiderbuyingselling Posted - 03/26/24

$EXEL new insider selling: 19205 shares. http://insiderbuyingselling.com/?t=EXEL

User Image Stocksrunner Posted - 03/25/24

📈 Monday Insider Trades Recap $AMREP Insider buys shares worth over $129k. $EXEL Director Garber Alan M sells shares worth over $460k. $LEGH Director buys $103k in stock. $LILA Director Paul A. Gould makes a $1.97M purchase. $OTLK Files to sell 21.43M common shares for holders. Stay informed with insider moves.

User Image ElijahJobs Posted - 1 month ago

$EXEL A bit more patience needed now. Light at the end of the tunnel soon. The stock did not do anything for more than 6 years but I have a reason to believe that the pain will be over soon. Once the patents get confirmed, EXEL will be bought by a BP right away. It has been brewing for more than 3 years, IMHO. All this can happen as early as April. JMO

User Image UncleStock Posted - 1 month ago

$CORT $UTHR $EXEL $VRTX suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

User Image quantguy Posted - 1 month ago

$EXEL bought Aug $26 call @ $1.60

User Image ron12 Posted - 1 month ago

$EXEL someone just needs to buy this company. It’s a damm piggy bank for the executives. Any big pharma could snag this if the Board or executives would work on behalf of the shareholders. Problem also is no damm pipeline. Thats a serious issue with one blockbuster only. Hopefully the patent gets extended accross the spectrum until 2030. Any negative news and we are at $17. Anyway, I own this in light of these issues.

User Image JR603 Posted - 1 month ago

$EXEL Tell me - am I the only dope in the universe waiting for this to do something? I've been holding for years and watched the cash grow to billions ........ yet crickets for SP action. Kindly give me some reason for holding much longer. TY.

User Image Acwild70 Posted - 1 month ago

$EXEL short attack?

User Image swingingtech Posted - 1 month ago

$BNTX $EXEL $NBIX https://wallstreetwaves.com/3-cutting-edge-biotech-stocks-sitting-on-the-brink-of-success/

User Image OtherOtttawaGuy Posted - 1 month ago

$EXEL Waiting for the news, liking the insider buys.

Analyst Ratings
Barclays Equal-Weight Apr 11, 24
JMP Securities Market Outperform Apr 10, 24
RBC Capital Outperform Feb 7, 24
Stifel Hold Feb 2, 24
Barclays Overweight Jan 30, 24
BTIG Buy Dec 19, 23
Citigroup Buy Dec 15, 23
JMP Securities Market Outperform Dec 14, 23
RBC Capital Outperform Dec 13, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Haley Patrick J. EVP, Commercial EVP, Commercial Dec 12 Sell 22.93 64,149 1,470,937 307,687 12/14/23
Haley Patrick J. EVP, Commercial EVP, Commercial Dec 12 Option 16.29 50,000 814,500 357,687 12/14/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Dec 13 Sell 23.01 25,000 575,250 533,345 12/14/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Nov 30 Sell 22.04 50,000 1,102,000 558,345 12/04/23
Aftab Dana CSO/EVP Disc & Trans.. CSO/EVP Disc & Trans Research Aug 30 Sell 22.47 4,600 103,362 399,943 09/01/23
MORRISSEY MICHAEL President and CEO President and CEO Aug 28 Option 15.31 360,000 5,511,600 945,496 08/30/23
Senner Christopher J. EVP and CFO EVP and CFO Aug 03 Option 14.74 120,000 1,768,800 631,631 08/07/23
Senner Christopher J. EVP and CFO EVP and CFO Aug 03 Sell 20.6 120,000 2,472,000 571,631 08/07/23
Haley Patrick J. EVP, Commercial EVP, Commercial Aug 03 Sell 20.67 30,553 631,531 285,467 08/07/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Aug 01 Sell 19.63 55,710 1,093,587 571,976 08/03/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Aug 01 Option 14.74 55,710 821,165 627,686 08/03/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Apr 03 Option 14.74 13,930 205,328 621,365 04/05/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Apr 03 Sell 20.01 38,930 778,989 582,435 04/05/23
WYSZOMIERSKI JACK L Director Director Mar 10 Sell 16.61 15,300 254,133 317,467 03/14/23
WYSZOMIERSKI JACK L Director Director Mar 10 Option 6.3 40,000 252,000 332,767 03/14/23
Garber Alan M Director Director Feb 21 Sell 17.49 40,000 699,600 31,417 02/23/23
Garber Alan M Director Director Feb 21 Option 6.3 40,000 252,000 71,417 02/23/23
FELDBAUM CARL B Director Director Feb 09 Sell 17.78 40,000 711,200 18,701 02/10/23
FELDBAUM CARL B Director Director Feb 09 Option 6.3 40,000 252,000 58,701 02/10/23
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 06 Sell 17.37 25,000 434,250 254,414 02/08/23
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 06 Option 4.2 25,000 105,000 279,414 02/08/23
MORRISSEY MICHAEL President and CEO President and CEO Jan 24 Option 4.2 100,000 420,000 440,655 01/26/23
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Option 4.2 20,000 84,000 430,958 12/16/22
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Sell 15.88 20,000 317,600 410,958 12/16/22
POSTE GEORGE Director Director Nov 29 Sell 16.68 40,000 667,200 193,189 12/01/22
POSTE GEORGE Director Director Nov 29 Option 6.3 40,000 252,000 233,189 12/01/22
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 12 Option 6.21 40,000 248,400 301,591 09/14/22
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 12 Sell 17.94 40,000 717,600 261,591 09/14/22
Senner Christopher J. EVP and CFO EVP and CFO Aug 11 Option 6.21 225,000 1,397,250 670,882 08/12/22
Haley Patrick J. EVP, Commercial EVP, Commercial May 27 Sell 18.21 18,812 342,567 239,818 06/01/22
WILLSEY LANCE Director Director May 12 Option 3.13 40,000 125,200 464,415 05/13/22
WILLSEY LANCE Director Director May 12 Sell 19.65 40,000 786,000 424,415 05/13/22
WYSZOMIERSKI JACK L Director Director Apr 04 Option 3.13 40,000 125,200 279,888 04/06/22
WYSZOMIERSKI JACK L Director Director Apr 04 Sell 23 6,696 154,008 273,192 04/06/22
Haley Patrick J. EVP, Commercial EVP, Commercial Mar 31 Option 6.21 20,000 124,200 279,191 04/04/22
Haley Patrick J. EVP, Commercial EVP, Commercial Mar 31 Sell 22.72 20,000 454,400 269,191 04/04/22
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Mar 28 Sell 22 18,000 396,000 605,236 03/30/22
Garber Alan M Director Director Mar 01 Option 3.13 40,000 125,200 52,718 03/03/22
Garber Alan M Director Director Mar 01 Sell 21 21,301 447,321 31,417 03/03/22
Hessekiel Jeffrey EVP and General Coun.. EVP and General Counsel Feb 24 Sell 20 18,000 360,000 555,361 02/28/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 25 Sell 19.53 31,238 610,078 198,476 02/28/22
PAPADOPOULOS STELIOS Director Director Feb 22 Sell 19.56 84,515 1,653,113 1,220,036 02/24/22
FELDBAUM CARL B Director Director Feb 22 Option 3.13 20,000 62,600 28,521 02/24/22
FELDBAUM CARL B Director Director Feb 22 Sell 19.49 20,000 389,800 8,521 02/24/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 03 Option 1.9 60,000 114,000 305,241 02/04/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 03 Sell 17.91 60,000 1,074,600 245,241 02/04/22
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Option 6.21 47,500 294,975 410,672 12/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Sell 17.44 47,500 828,400 363,172 12/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Oct 15 Option 6.21 47,500 294,975 458,740 10/15/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Oct 15 Sell 21.92 47,500 1,041,200 411,240 10/15/21